Trial Profile

A Phase I-II, Blinded, Randomized, Placebo-controlled Study of a T Cell Priming Next-generation Vaccine Against Coronavirus Disease in Healthy Adults

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PepGNP-SARSCoV2 (Primary)
Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease; Severe acute respiratory syndrome
Focus Adverse reactions
Acronyms naNO-COVID 2
Sponsors Gylden Pharma

Most Recent Events

24 Feb 2025 Protocol was amended as dose changed from 38.3ug to 47.8ug.
24 Feb 2025 Planned End Date changed from 23 Oct 2024 to 1 Dec 2026.
24 Feb 2025 Planned primary completion date changed from 23 Mar 2024 to 1 Jun 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com